Clinical Trial Update: Adenosine 2A Receptor Antagonism and AIH in ALS [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on an Adenosine A2A receptor antagonist approach for amyotrophic lateral sclerosis (Phase 1/Phase 2; active not recruiting).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Adenosine A2A receptor antagonist (Adenosine A2A receptor antagonist)

Snippet

Sponsor: University of Florida | Conditions: ALS | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING